Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jul 1;21(13):2886-8.
doi: 10.1158/1078-0432.CCR-14-3012. Epub 2015 Jan 21.

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

Marcia R Campbell  1 , Mark M Moasser  2
Affiliations
Comment

HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive

Marcia R Campbell et al. Clin Cancer Res. .

Abstract

Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figures

Figure 1
Figure 1
A schematic summary of numerous genetic or expression scenarios of the HER family wherein breast cancer cells may be driven by the HER family of receptors or their ligands. The scenarios depicted are ones for which there is at least some evidence from clinical studies or cell lines to suggest a functional role. Many other hypothetical scenarios are plausible, but without any evidence. All these scenarios are expected to be sensitive to an EGFR/HER2 kinase inhibitor such as lapatinib and captured by a lapatinib screen. The first scenario represents the clinically diagnosed HER2-positive subtype of breast cancer. All other potential scenarios fall under the umbrella of clinical HER2-negative breast cancer and currently not assayed or identified in the course of clinical care.
See this image and copyright information in PMC

Comment on

References

    1. Leary A, Evans A, Johnston SRD, A’Hern R, Bliss JM, Sahoo R, et al. Antiproliferative effect of lapatinib in HER2-positive and HER2-negative/HER3-high breast cancer: results of the presurgical randomized MAPLE trial (CRUK E/06/039) Clin Cancer Res. 2014 Epub ahead of print. - PubMed
    1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45. - PubMed
    1. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. - PubMed
    1. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28:1215–23. - PubMed
    1. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010;16:1373–83. - PMC - PubMed

Publication types

MeSH terms